Life stage

Menopause

Postmenopausal years, including bone, metabolic, and cardiovascular health considerations.

Teriparatide is approved for postmenopausal osteoporosis. Tirzepatide and semaglutide are approved for chronic weight management and type 2 diabetes in adults, including postmenopausal women, but life-stage-specific analyses by menopausal status are not established.

Relevant approved medicines and indications

Teriparatide

Parathyroid hormone analog (peptide fragment)

Tirzepatide

Dual GIP/GLP-1 receptor agonist

Semaglutide

GLP-1 receptor agonist

Evidence gaps and exclusion patterns

Bone-muscle outcomes
Cardiometabolic sex analyses

Recent audits and articles

Were women studied? Fracture Prevention Trial (NCT00670501) and related osteoporosis trials

Teriparatide osteoporosis trials included large numbers of postmenopausal women; sex-comparative analysis is not applicable to these women-only cohorts.

Questions for clinician conversations

What evidence exists for people in my life stage?
What are the known unknowns for this medicine in this population?
How should I monitor for adverse effects?

Author

Ian Gauntt

RN, BSN — 10 years as a critical care nurse

Medical reviewer

Medical Reviewer (Pending Assignment)

Medical review pending assignment by a licensed clinician.

Last reviewed 2026-08-01Next review 2026-11-01

Medical disclaimer: Her Health Peptides publishes educational, source-linked summaries. We do not provide individualized medical advice, diagnosis, or treatment recommendations. Always talk with a licensed clinician about your specific situation, especially if you are pregnant, breastfeeding, planning pregnancy, or taking other medicines.